The human papillomavirus (HPV) vaccine market size was valued at USD 8.14 billion in 2024 and is expected to reach USD 27.36 billion by 2032, growing at a CAGR of 16.38% from 2025 to 2032.
To Get More Information on Human Papillomavirus (HPV) Vaccine Market - Request Sample Report
The global human papillomavirus (HPV) vaccine market is being driven by the increasing prevalence of HPV associated diseases across the world and the advent of vaccination programs to curb these cases. With one in three men around the world infected with genital HPV, the WHO noted the need for general vaccination. HPV causes almost 95% of cervical cancers and also has associations with oropharyngeal, anal, and penile cancers. Nearly 36,000 cases of HPV-related cancers occur each year in the U.S., the CDC says. Global vaccination coverage is inequitable.
In January 2025, the Indian government announced that the nationwide rollout of the HPV vaccine will begin in a few months, focusing on adolescent girls to curb cervical cancer rates.
For instance, 2022 WHO data showed that only 21% of girls received the full vaccine course worldwide, underscoring a missed opportunity. Higher government and private investments in preventive healthcare, supportive regulatory approvals, and R&D investments made by companies like Merck & Co. and GlaxoSmithKline, early entrants in the HPV vaccine market, have also contributed, in addition to market development. Gavi, the Vaccine Alliance, supported programs have also improved supply access in low- and middle-income countries. Increasing awareness and application in the national immunization schedule are other factors promoting the growth of the human papillomavirus (HPV) vaccine market. Strong clinical pipelines and the WHO’s call to eliminate cervical cancer will continue to boost the HPV vaccine market size in the future.
In January 2025, Ethiopia shifted to a single-dose HPV vaccination schedule, which significantly increased the number of vaccinated girls across the country.
Drivers:
Rising Immunization Initiatives, Technological Advancements, and Government Support Propel Market Expansion
The growth of the human papillomavirus (HPV) vaccine market is driven by the increasing number of government-run national HPV vaccination programs, growing public awareness of HPV, and innovative product development. As of 2023, more than 125 countries have introduced the HPV vaccine into national immunization programs (WHO), resulting in substantial demand-side expansion.
Large pharmaceutical companies like BioNTech and Moderna are involved in developing the mRNA-based HPV vaccines, indicating increased R&D momentum. Available NIH funding data show that R&D for U.S.-based HPV vaccine projects has been awarded more than USD 50 million in federal grants over the past three years. Further boosting access is regulatory assistance like the FDA’s extended Gardasil 9 approval for people as old as 45. Supply-side conditions are also on the mend, as companies ramp up production to cope with expanding global demand, particularly in underserved areas. Global partnerships, including partnerships like those between UNICEF and vaccine manufacturers, help secure procurement and delivery in low-income countries, enhancing and leveraging the supply chain and access. These are drivers of long-range human papillomavirus (HPV) vaccine market share growth.
In January 2025, Bangladesh reported a 93% coverage rate in its national HPV vaccination program, highlighting the success of routine immunization efforts.
Restraints:
Supply Chain Barriers, Vaccine Hesitancy, and Uneven Global Coverage Impede Market Growth
While high-income countries have included HPV vaccines in their routine schedules, only 41% of low-income countries have an adequate supply, the group said, citing Gavi. Vaccine distribution is also a challenge and may be protracted in time and inefficient, due to the lack of availability of raw material, and cold-chain logistics for safe transport and storage, particularly in remote locations. Moreover, public mistrust and misinformation about vaccine safety continue to dampen vaccination uptake.
A 2022 study in JAMA Pediatrics found that 20% of parents in the U.S. were reluctant to vaccinate adolescents based on safety worries, even though the contrary was well-established. However, time-intensive regulatory approval and non-uniform implementation of guidelines within countries continue to stifle market expansion. For instance, in some low-income countries, there are undefined guidelines for age-based vaccine delivery or booster doses, which leads to limited continuity of coverage. The newer vaccines are prohibitively expensive for countries not funded through Gavi or WHO programs. In addition to this, vaccines are costly to develop and approve, with USD 100 m-plus price tags on clinical trials, limiting many smaller biotech firms’ participation in the market. Together, these hurdles have all but muted the otherwise robust prospects of the human papillomavirus (HPV) vaccine market.
By Type
Polyvalent HPV vaccines, mainly Merck’s Gardasil and Gardasil 9, contributed to a share of over 85% of the overall human papillomavirus (HPV) vaccine market in 2024. Their comprehensive coverage of multiple HPV strains, which include types 6, 11, 16, and 18 that are responsible for most HPV-related cancers and genital warts, renders them the choice vaccine for global consumption.
Concerning it, the bivalent vaccine, only against HPV types 16 and 18, Cervarix, developed by GSK, has faced decreased acceptance as the narrower protection spectrum of actions somehow lowers demand. The strongest segment of growth is also the polyvalent, and has followed a growth path influenced by enhanced regulatory clearances and extended age range indications (Adults up to 45 years of age) and by increased uptake in national vaccination programs.
By Disease Indication
The HPV-related cancer segment accounted for a major share of around 70% in 2024, and the rising importance of cancer prevention in the global healthcare programs and policies is contributing to its dominant share. The segment remains a focus of considerable investment in health care resources and attention because HPV is responsible for almost all cases of cervical cancer; as well, a high proportion of anal, oropharyngeal, and penile cancer cases. The most rapidly increasing section continues to be HPV-associated cancers, with rising cancer incidents, increased screening, and government-promoted cancer eradication program-related vaccinations.
By Distribution Channel
Hospitals and retail pharmacies dominated the market, holding a market share of around 60% in 2024. Being widely available and well integrated into routine public vaccination programs, they represent the most important distribution channel. The segment of hospitals and retail pharmacies is also growing at the fastest CAGR, driven by the growing availability of vaccines in outpatient care, the development of healthcare infrastructure in developing countries, and growing consumer confidence in institutional vaccination services. And these channels are now pivotal for adolescent and adult HPV vaccination efforts.
In 2024, North America remained at the forefront in the human papillomavirus vaccine market owing to the presence of a robust healthcare system, high vaccination coverage, stringent regulations, and organized vaccination schedules. The U.S. human papillomavirus (HPV) vaccine market size was valued at USD 3.44 billion in 2024 and is expected to reach USD 10.96 billion by 2032, growing at a CAGR of 15.62% from 2025 to 2032. The U.S. was leading, with widespread public-private vaccination campaigns having supported over 77% of adolescent girls and 74% of boys in receiving at least one dose of the HPV vaccine, according to CDC data. Also, robust government support, such as the Vaccines for Children (VFC) program, guarantees steady need and access. Canada is gradually advancing its vaccine campaign with school-based programs nationwide and gender-neutral immunization policies. In Mexico, where coverage rates are still climbing, regional cooperation, with the support of the WHO, is also helping.
The HPV vaccine market in APAC is estimated to grow at the fastest rate due to high cancer awareness, growing government-aided programs for immunization, and a large population of adolescents. India, with its millions of school-age girls, is a critical factor in the future national rollout of its HPV vaccine in 2025. Serum Institute’s less expensive vaccine, which is quadrivalent, is expected to improve access in both urban and rural areas. China is also advancing with pilot immunization, scaling up of public education, and Australia continues to lead the share of young people who are vaccinated in school-based programs, reaching over 80% among adolescents. Japan and South Korea are increasing the use of post-safety reevaluation of HPV vaccines.
Europe is a mature market, and growth has been somewhat slower because of saturation in high-income countries and vaccine hesitancy in some populations. Demand is highest in the UK, which just entered the market with over 85% coverage rates in school-based programs and a gender-neutral policy with benefits offered to boys. France and Germany have stepped up HPV education to thwart hesitancy, and Italy and Spain have broadened regional immunization policies. Eastern European nations such as Poland and Turkey are catching up with the help of EU funds and awareness campaigns. While there has been good initial coverage, misinformation and vaccine safety concerns have slightly held the adoption rates down in some countries.
LAMEA is witnessing a steady and promising growth, as more healthcare education, WHO-Gavi-backed initiatives, and government cancer prevention commitments are adopted. Brazil is the region’s front-runner, with vaccination rates of nearly 70% among schoolchildren, achieved through large, school-based vaccination campaigns and public awareness campaigns. Argentina is rapidly increasing its HPV vaccination and has multi-year plans on the road. In South Africa, in the Middle East & Africa region, public-sector vaccination initiatives of HPV vaccines are performed, and the use of HPV vaccines in school outreach programs is included.
Prominent human papillomavirus (HPV) vaccine players operating in the market include Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Pfizer Inc., Inovio Pharmaceuticals Inc., Walvax Biotechnology Co., Ltd., Bharat Biotech International Ltd., Johnson & Johnson Services, Inc., Moderna, Inc., and Gilead Sciences, Inc.
In January 2025, Merck is facing a USD 8 billion lawsuit related to Gardasil, with a jury trial underway addressing allegations about vaccine-related side effects.
In January 2025, GSK discontinued its Phase 2 HPV vaccine candidate due to a lack of best-in-class potential, halting further development.
| Report Attributes | Details |
| Market Size in 2024 | USD 8.14 billion |
| Market Size by 2032 | USD 27.36 billion |
| CAGR | CAGR of 16.38% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Bivalent, Polyvalent) • By Disease Indication (HPV Related Cancer, Genital Warts) • By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Merck & Co., Inc., GlaxoSmithKline plc (GSK), Serum Institute of India Pvt. Ltd., Sanofi Pasteur SA, Pfizer Inc., Inovio Pharmaceuticals Inc., Walvax Biotechnology Co., Ltd., Bharat Biotech International Ltd., Johnson & Johnson Services, Inc., Moderna, Inc., and Gilead Sciences, Inc. |
Ans. During the forecast period, the CAGR for the Human Papillomavirus (HPV) Vaccine Market is 16.38%.
Ans. By 2032, the Human Papillomavirus (HPV) Vaccine is expected to be worth USD 27.36 Billion.
Ans. During the projection period, the polyvalent sector is likely to be the market leader.
Ans. In 2024, North America dominated the worldwide market.
Ans. The effectiveness of the products in lowering the risk of cancer and genital warts, as well as government support in raising immunisation knowledge, are expected to increase vaccination usage.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of HPV-Related Conditions (2024)
5.2 Vaccination Coverage and Uptake Rates (2024), by Region
5.3 HPV Vaccine Doses Distributed or Administered, by Region (2021–2032)
5.4 Healthcare Spending on HPV Vaccination, by Region and Payer Type (Government, Insurance, Private, Out-of-Pocket), 2024
5.5 Cost per Vaccinated Individual and Cost-Effectiveness Analysis
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Human Papillomavirus (HPV) Vaccine Market Segmentation by Type
7.1 Chapter Overview
7.2 Bivalent
7.2.1 Bivalent Market Trends Analysis (2021-2032)
7.2.2 Bivalent Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Polyvalent
7.3.1 Polyvalent Market Trends Analysis (2021-2032)
7.3.2 Polyvalent Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Human Papillomavirus (HPV) Vaccine Market Segmentation By Disease Indication
8.1 Chapter Overview
8.2 HPV Related Cancer
8.2.1 HPV Related Cancer Market Trend Analysis (2021-2032)
8.2.2 HPV Related Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Genital Warts
8.3.1 Genital Warts Market Trends Analysis (2021-2032)
8.3.2 Genital Warts Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Human Papillomavirus (HPV) Vaccine Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital & Retail Pharmacies
9.2.1 Hospital & Retail Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital & Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Government Suppliers
9.3.1 Government Suppliers Market Trends Analysis (2021-2032)
9.3.2 Government Suppliers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2021-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.4 North America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.2.5 North America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.6.2 USA Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.2.6.3 USA Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.7.2 Canada Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.2.7.3 Canada Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.2.8.2 Mexico Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.2.8.3 Mexico Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.4 Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.5 Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel(2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.1.6.2 Germany Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.1.6.3 Germany Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.7.2 France a Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.7.3 France Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.8.2 UK Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.8.3 UK Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.9.2 Italy Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.9.3 Italy Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.10.2 Spain Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.10.3 Spain Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.12.3 Poland Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.12.3 Poland Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.13.2 Turkey Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.13.3 Turkey Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel(2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.6.2 China Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.6.3 China Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.7.2 India Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.7.3 India Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.8.2 Japan Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.8.3 Japan Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.9.2 South Korea Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.9.3 South Korea Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.10.2 Singapore Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.10.3 Singapore Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.11.2 Australia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.11.3 Australia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.6.2 UAE Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.5.6.3 UAE Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.8.2 Qatar Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.5.8.3 Qatar Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.9 2 South Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts By Disease Indication (2021-2032) (USD Billion)
10.5.9 3 South Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.4 Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.6.5 Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.6.2 Brazil Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.6.6.3 Brazil Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.7.2 Argentina Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.6.7.3 Argentina Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, by Type (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Disease Indication (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Human Papillomavirus (HPV) Vaccine Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12. Company Profiles
12.1 Merck & Co., Inc.
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 GlaxoSmithKline plc (GSK)
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Serum Institute of India Pvt. Ltd.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Sanofi Pasteur SA
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Pfizer Inc.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Inovio Pharmaceuticals Inc.
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Walvax Biotechnology Co., Ltd.
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Bharat Biotech International Ltd.
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Johnson & Johnson Services, Inc.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Moderna, Inc.
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Type
Bivalent
Polyvalent
By Disease Indication
HPV Related Cancer
Genital Warts
By Distribution Channel
Hospital & Retail Pharmacies
Government Suppliers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players